Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term combination. Found 24 abstracts

no pagination
Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect (TM) versus Veridex CellSearch (TM) system. International journal of cancer. 2012 Apr;130(7):1590-7.   PMCID: *
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2012 Dec;127(3):538-43.   PMCID: PMC3568489
Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 2012 Oct;107(8):1268-76.
Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 2012 Oct;107(8):1268-76.   PMCID: PMC3494424
Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecologic Oncology. 2012 Dec;127(3):456-61.   PMCID: *
Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS, Zimmitti G, Curley SA, Charnsangavej C, Aloia TA, Vauthey JN. Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point Before Resection of Hepatic Colorectal Metastases. Journal of Clinical Oncology. 2012 Dec;30(36):4566-72.   PMCID: PMC3518730
Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MJ, Lourenco L, Wang L, Chen A, Moore MJ. Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Cancer Research. 2012 Nov;18(21):6023-31.
Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple Myeloma. Journal of the National Comprehensive Cancer Network. 2011 Oct;9(10):1146-83.   PMCID: not NIH funded
Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. A Phase 2 Trial of Erlotinib in Patients With Previously Treated Squamous Cell and Adenocarcinoma of the Esophagus. Cancer. 2011 Apr;117(7):1409-14.   PMCID: PMC3116987
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu JM, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncology. 2010 Jan;11(1):21-8.   PMCID: not NIH funded
Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J. A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer A Gynecologic Oncology Group Trial. International Journal of Gynecological Cancer. 2010 Oct;20(7):1137-41.   PMCID: PMC3079178
Svahn TH, Niland JC, Carlson RW, Hughes ME, Ottesen RA, Theriault RL, Edge SB, Schott AF, Bookman MA, Weeks JC. Predictors and Temporal Trends of Adjuvant Aromatase Inhibitor Use in Breast Cancer. Journal of the National Comprehensive Cancer Network. 2009 Feb;7(2):115-21.   PMCID: No NIH
Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2006 Apr;295(14):1658-67.
Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study. Journal of Clinical Oncology. 2005 Dec;23(34):8646-54.
Mulcahy MF, Loehrer PJ, Meropol NJ, Rademaker AW, Benson AB. A phase I study of docetaxel, cisplatin, 5-fluorouracil and leucovorin. Oncology. 2005 Jan;68 (4-6):479-84.
Gervasoni JE, Hindenburg AA, Vezeridis MP, Schulze S, Wanebo HJ, Mehta S. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis. Anticancer research. 2004 Sep;24(5A):2617-26.
Komaki R, Seiferheld W, Ettinger D, Lee JS, Movsas B, Sause W. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: Long-term follow-up of RTOG 92-04. International Journal of Radiation Oncology Biology Physics. 2002 Jul;53(3):548-57.
Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002 Jun 15;99(12):4336-42.
Alpaugh RK, von Mehren M, Palazzo I, Atkins MB, Sparano JA, Schuchter L, Weiner LM, Dutcher JP. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon. Medical Oncology. 1998 Sep;15(3):191-8.
Langer CJ, Schaebler D, Sauter E, DeMaria D, Johnson C, Reilly DM, Clark J, Leighton J, Aks C, Litwin S, Ridge JA. Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 1998 Aug;20(5):385-91.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term combination

combination chemotherapy trial expression bevacizumab carcinoma cisplatin cancer recurrence colorectal-cancer metastatic breast-cancer growth-factor receptor 1990 lkman j-journal of the national cancer institute-v82-p4 survival pharmacokinetics clinical-trials tumors adjuvant therapy randomized-trial leucovorin endothelial growth-factor growth radiation-therapy concurrent dexamethasone paclitaxel axitinib-docetaxel-capecitabine-solid tumours receptors postmenopausal women tamoxifen therapy ag-013736 squamous-cell carcinoma doxorubicin cell lung-cancer necrosis donor lymphocyte infusions mutations tamoxifen bone-marrow transplantation long-term survival Endometrial cancer Aflibercept-VEGF Trap-Toxicity-Fibroblast growth factor complications accelerated fractionation colony-stimulating factor her2 status fluorouracil plus leucovorin term follow-up cytogenetics prognostic scoring system Aromatase inhibitors antiangiogenic therapy open-label factor receptor rates apoptosis folinic acid therapy-oncology-group stem-cell transplantation thalidomide plus neoadjuvant chemotherapy gene plus cetuximab apoptosis induction bisphosphonates high response family proteasome inhibitor mgi-114 primary amyloidosis breast neoplasms lung-cancer squamous cancer esophageal cancer-erlotinib-response evaluation 5-fluorouracil anastrozole NCCN Guidelines myelodysplastic syndrome oncology-group predictive markers interleukin-2 drug molecular-detection pegylated liposomal doxorubicin epidemiology estrogen-receptor radiation therapy 2009 carthy pl-blood-v114 vegf NCCN Clinical Practice Guidelines stem cell transplant clinical trial gastroesophageal junction ganglioside epidermal-growth-factor 6-hydroxymethylacylfulvene monoclonal-antibody positron-emission-tomography evolving technology GOG 2-chlorodeoxyadenosine Platinum-sensitive ovarian cancer pathological response epithelial-cells C-reactive protein carcinomas c225 lung cancer squamous-cell-carcinoma metaanalysis Irofulven General & Internal Medicine resistance Prognostic markers oxaliplatin therapy Waldenstrom's monoclonal protein solid interferon p53 blockade t-lymphocytes Pelvic radiation Cervical cancer-Cetuximab gefitinib cell-death novel therapies advanced squamous cell carcinoma of the supportive therapies metastatic breast cancer paclitaxel multicenter stage iib oncology group rtog oncology-technology-assessment advanced gastric-cancer recombinant interferon alpha radiotherapy circulating tumor cells high-dose therapy rt-pcr 2004 nseca r-cancer res-v64-p1546 prognostic value fluorouracil peripheral-blood immunomodulatory drugs oral capecitabine gastric cancer phase I trials-docetaxel regimen atac arimidex chemosensitivity hmaf 2011 carthy p-haematologica-v96-ps23 monoclonal antibody
Last updated on Wednesday, February 05, 2020